Time to benefit of incretin-based therapies in adiposity-related heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis
Patients know how quickly to expect improvement from newer diabetes drugs used for heart failure, helping them make informed decisions about starting treatment.
A systematic review and meta-analysis characterized the time-to-clinical-benefit of GLP-1 receptor agonists in adiposity-related heart failure with preserved or mildly reduced ejection fraction, a large and underserved patient group. The time-to-benefit data provide actionable guidance on how quickly patients can expect improvement, directly informing treatment initiation decisions and adherence counseling in HFpEF patients.
What the study was
- Study design
- Systematic review and meta-analysis of RCTs on incretin-based therapies in HFpEF/HFmrEF
- Population
- Adiposity-related HFpEF/HFmrEF patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- J Card Fail
Why it surfaced
High-relevance meta-analysis providing time-to-benefit data for incretin therapy in HFpEF/HFmrEF — a major clinical gap; directly relevant to GLP-1/cardiometabolic watchlist with large patient population impact.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.